B
Beijing Van Enkel Biotechnology
Developing novel anti-cancer drugs targeting signaling pathways
About Beijing Van Enkel Biotechnology
Beijing Van Enkel Biotechnology, also known as FindCure Biosciences, is a clinical-stage biopharmaceutical company founded in 2019. The firm is dedicated to the research and development of innovative anti-cancer drugs, concentrating on targeting signaling pathways and immunotherapy. Its pipeline includes small molecule targeted drugs as well as macromolecular proteins and antibody drugs, all protected by independent intellectual property rights.
The company operates from the Beijing Economic and Technological Development Zone and has a presence in Zhongshan, Guangdong. In recent years, FindCure has secured significant funding to advance its clinical programs. A notable Series A funding round, which raised tens of millions of yuan, was supported by a consortium of investors including Hecheng Capital, Huaying Health, Renxi Fund, Yishang Huicheng, and Dilianxing. This followed earlier investments from Share Capital and South China Venture Capital.
FindCure aims to develop first-in-class or best-in-class drugs with the potential for breakthrough performance in the global market. The company actively participates in the scientific community, hosting forums on the application of nuclear medicine in oncology and achieving recognition in national innovation and entrepreneurship competitions.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 21.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Oncology, Drug Development, Pharmaceutical, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Feb 2026 | $28M | $110M | Hecheng Capital · Renxi Fund · Zhongzhi Pharmaceutical Group | ↗ |
| SERIES A✓Equity / VC | Sep 2023 | $2.8M | $11M | Huaying Health Fund · Hecheng Capital · Renxi Fund · Beijing Yishang Huicheng | ↗ |
Growth signals
Latest recorded traffic for Beijing Van Enkel Biotechnology is 170 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
| China | Operational | — | — | — | |
Twinpig BiolabPeptide-drug conjugate platform for immuno-oncology therapies |
Seoul, South Korea | Operational | |||
| China | Operational | ||||
Cytospire TherapeuticsHarnessing the immune system to create next-generation cancer treatments |
London, United Kingdom | Operational | |||
Link Cell TherapiesA True CAR T Cell AND-Gate |
San Carlos, United States | Operational | |||
AtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance |
L'Hospitalet de Llobregat, Spain | Operational | |||
Celeris TherapeuticsPredicting biomolecular interactions and designing drugs for incurable diseases |
Graz, Austria | Operational | |||
ASYLIACompanion Diagnostics For Immunotherapy | Asylia Diagnostics |
Beerse, Belgium | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Beijing Van Enkel Biotechnology in its local ecosystem
The Beijing Van Enkel Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
- HFHuaying Health Fund
- HCHecheng Capital
- RFRenxi Fund
- BHBeijing Yishang Huicheng
- DIDilianxing
- ZGZhongzhi Pharmaceutical Group
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Beijing Van Enkel Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Beijing Van Enkel Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







